The online portal to the latest developments in laboratories and laboratory equipment
Friday, 15 October 2010
Efficacy study of olesoxime in spinal muscular atrophy
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the initiation of the pivotal efficacy study of olesoxime in the rare, neurodegenerative condition, spinal muscular atrophy (SMA). The study is substantially funded by Trophos’ partnership with the Association Française contre les Myopathies (AFM) (see release of 19 March 2009). The trial protocol has benefited from the EMA Protocol Advice procedure. Efficacy results are expected in 2013.
Labels: laboratory, drug discovery
Trophos SA
Positive Phase I data for ZP1848 in Crohn’s Disease
Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, today announced positive results from a Phase I trial of ZP1848 for the treatment of Crohn’s disease.
ZP1848 is a potent and selective GLP-2 agonist discovered by Zealand Pharma that is targeted to offer a novel treatment option for patients with Crohn’s disease due to its regenerative effect on the intestinal surface and enhancement of intestinal function.
ZP1848 is a potent and selective GLP-2 agonist discovered by Zealand Pharma that is targeted to offer a novel treatment option for patients with Crohn’s disease due to its regenerative effect on the intestinal surface and enhancement of intestinal function.
Labels: laboratory, drug discovery
Zealand Pharma A/S
High volume plate optimised for high yield yeast production
A 24-well microplate, with a working volume of 10ml / well, has been developed by Porvair Sciences Ltd. for large scale, high yield growth of yeast.
Produced under class 10,000 clean room conditions from virgin polypropylene, the new 24-well plate contains no contaminants that may leach out and affect yeast growth. The wells of the high volume plate are rectangular in shape with a 'v' bottom to facilitate easy yeast concentration and recovery.
Produced under class 10,000 clean room conditions from virgin polypropylene, the new 24-well plate contains no contaminants that may leach out and affect yeast growth. The wells of the high volume plate are rectangular in shape with a 'v' bottom to facilitate easy yeast concentration and recovery.
Labels: laboratory, drug discovery
Porvair Sciences Ltd
Webinar: Deploying LIMS as an integral component for manufacturing operations
LabVantage will host a live webinar on deploying laboratory information management systems (LIMS) as an integral component for manufacturing operations excellence.
Featuring speakers from Gartner and CF Industries, this webinar will be conducted on Wednesday, October 27, 2010 at 10 am EDT, and include an interactive question & answer session. To register for this 40-minute webinar, please go to www.lims.com/deployment
Featuring speakers from Gartner and CF Industries, this webinar will be conducted on Wednesday, October 27, 2010 at 10 am EDT, and include an interactive question & answer session. To register for this 40-minute webinar, please go to www.lims.com/deployment
Labels: laboratory, drug discovery
LabVantage
AnaSpec introduces SensoLyte HAT (p300) and HAT (pCAF) assay kits
AnaSpec has released two HAT (histone acetyltransferase) fluorimetric kits adding to its list of epigenetics research products.
The SensoLyte p300 Assay Kit provides a convenient assay for the screening of enzyme inhibitors and for continuous measurement of p300 activity. For added convenience, this kit includes two peptide substrates: histone H3 (1-21) peptide and non-histone p53 peptide (368-386). After incubation with acetyl CoA and the substrate, the p300 enzyme generates acetylated H3 or p53 peptide and CoASH. The thiol groups of CoASH can be detected with a fluorogenic reagent at excitation/emission=389nm/513nm.
The SensoLyte p300 Assay Kit provides a convenient assay for the screening of enzyme inhibitors and for continuous measurement of p300 activity. For added convenience, this kit includes two peptide substrates: histone H3 (1-21) peptide and non-histone p53 peptide (368-386). After incubation with acetyl CoA and the substrate, the p300 enzyme generates acetylated H3 or p53 peptide and CoASH. The thiol groups of CoASH can be detected with a fluorogenic reagent at excitation/emission=389nm/513nm.
Labels: laboratory, drug discovery
AnaSpec
BioFocus extends collaboration with Chiesi
BioFocus, the provider of integrated gene-to-clinical candidate drug discovery services, announced today that it has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. Total value for the collaboration with Chiesi has now reached €2.5 million.
Labels: laboratory, drug discovery
BioFocus,
Chiesi Farmaceutici
Five minute test for superbug
Universal Sensors is rising to the challenge of creating a hand-held device – able to detect the presence of C.difficile or MRSA in hospital wards within 5 minutes of swabbing – following the success of its initial project.
The company, which designs and manufactures sensitive, fast and versatile biosensors, has been awarded a Phase2 Small Business Research Initiative (SBRI) contract from the UK Department of Health to create a product.
The company, which designs and manufactures sensitive, fast and versatile biosensors, has been awarded a Phase2 Small Business Research Initiative (SBRI) contract from the UK Department of Health to create a product.
Labels: laboratory, drug discovery
Universal Sensors
Cherwell launches new website for prepared media and environmental monitoring
Cherwell Laboratories, specialists in the manufacture of prepared microbiological media and supply of environmental monitoring instrumentation for pharmaceutical and related industries, has launched a new website to provide enhanced application and product information.
www.cherwell-labs.co.uk also offers improved navigation options to enable visitors to readily browse and find the information that they require.
www.cherwell-labs.co.uk also offers improved navigation options to enable visitors to readily browse and find the information that they require.
Labels: laboratory, drug discovery
Cherwell Laboratories
Cell migration assay reduces cost of high content screening
AMSBIO has announced the launch of the first of a new generation of cell migration assays designed specifically for fully automated high throughput screening (HTS) utilizing high content screening (HCS) and high content imaging (HCI) systems.
The new Oris Pro 384 Cell Migration Assay uses a non-toxic biocompatible gel (BCG) to form a centrally located and temporary cell-free zone on cell culture surfaces in a 384-well format.
The new Oris Pro 384 Cell Migration Assay uses a non-toxic biocompatible gel (BCG) to form a centrally located and temporary cell-free zone on cell culture surfaces in a 384-well format.
Labels: laboratory, drug discovery
AMSBIO
Licensing and collaboration agreement to automate sample analysis for forensics and drug discovery
GE Healthcare and Hamilton Robotics have entered into a licensing and collaboration agreement to develop a fully automated workflow for sample handling and processing from FTA substrates. Financial terms are not being disclosed.
Labels: laboratory, drug discovery
GE Healthcare,
Hamilton Robotics
Automation increases neonatal screening throughput
Astoria-Pacific International has chosen Tecan’s Freedom EVO liquid handling platform to automate its new SPOTCHECK Pro Neonatal Screening assays for biotinidase and GALT (galactose-1-phosphate uridyltransferase).
Alana Lerch, Newborn Screening Product Manager at Astoria-Pacific International, explained: “SPOTCHECK Pro is a microplate-based system, offering end–to–end automation for routine neonatal testing. The Freedom EVO platform is able to fully integrate all the modules necessary for complete automation of our assays, offering customers the ability to run overnight and at weekends, with minimal maintenance requirements.
Alana Lerch, Newborn Screening Product Manager at Astoria-Pacific International, explained: “SPOTCHECK Pro is a microplate-based system, offering end–to–end automation for routine neonatal testing. The Freedom EVO platform is able to fully integrate all the modules necessary for complete automation of our assays, offering customers the ability to run overnight and at weekends, with minimal maintenance requirements.
Labels: laboratory, drug discovery
Tecan Trading AG
Thursday, 14 October 2010
Rapid analysis of liquids by FTIR spectroscopy
A2 Technologies has announced its new integrated FTIR analyzer designed for the rapid analysis of liquids by FTIR spectroscopy. Based on A2's widely used ML analyzer, the high performing FTIR spectrometer that occupies just 8 square inches on a lab bench, the ML with DialPath Technology represents a completely new approach to the analysis of liquid samples.
The DialPath technology features a tumbler-like optical head that can be rotated into position to provide one of three, factory set, selectable sample pathlengths between 30 and 250 microns.
The DialPath technology features a tumbler-like optical head that can be rotated into position to provide one of three, factory set, selectable sample pathlengths between 30 and 250 microns.
Labels: laboratory, drug discovery
A2 Technologies,
v
Custom monoclonal antibody generation
MorphoSys AG's research and diagnostic antibodies unit AbD Serotec has signed a two year contract for the supply of custom monoclonal antibodies with Research Councils UK Shared Services Centre Limited (RCUK SSC Ltd). RCUK SSC Ltd has been set up by the seven Research Councils of the UK (RCUK) to provide centralized services to the Research Councils and their institutes in various areas including procurement.
Labels: laboratory, drug discovery
AbD Serotec,
MorphoSys AG
Wednesday, 13 October 2010
Dr Christel Fenge is new Vice President of Marketing, Fermentation Technologies
Dr Christel Fenge joined the Sartorius Stedim Biotech group as Vice President of Marketing for Fermentation Technologies. She will be globally responsible for the management of the product portfolio of multi- and single-use bioreactors, which currently represents the most comprehensive range in the industry.
Most recently Christel Fenge held the position as the General Manager of ,Recipharm Biologics. Previous posts included senior management positions in biopharmaceutical development at AstraZeneca.
Most recently Christel Fenge held the position as the General Manager of ,Recipharm Biologics. Previous posts included senior management positions in biopharmaceutical development at AstraZeneca.
Rapid identification of contaminating gDNA in RNA samples
Lab901 has announced the availability of a new technical note titled ‘Rapid identification of contaminating gDNA in total RNA samples using ScreenTape R6K.’ The technical note can be downloaded from www.lab901.net/images/pdfs/lmm-043-a.pdf.
Labels: laboratory, drug discovery
Lab901
High sensitivity GPC triple detector system for polymer and protein characterisation
The new SEC-3010 triple detector system from Dorton Analytical Ltd sets a new standard for high performance characterisation of polymers and proteins using Gel Permeation Chromatography / Size Exclusion Chromatography (GPC/SEC).
The SEC-3010 triple detector system is a complete GPC system comprising pump, autosampler, viscosity/refractive index detector, multi-angle light scattering detector and ParSEC enhanced software.
The SEC-3010 triple detector system is a complete GPC system comprising pump, autosampler, viscosity/refractive index detector, multi-angle light scattering detector and ParSEC enhanced software.
Labels: laboratory, drug discovery
Dorton Analytical Ltd
Tuesday, 12 October 2010
BioFocus and the National Cancer Institute sign compound management agreement
BioFocus announced today that its Compound Focus subsidiary has signed an agreement with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million (€3.7 M), with two one-year extension options.
Labels: laboratory, drug discovery
BioFocus
Integrated early stage drug development platforms
Quotient Bioresearch, a leading provider of early and specialist drug development services, will be highlighting its unique Translational Pharmaceutics and Synthesis-to-Clinic platforms at FIP Pharmaceutical Sciences World Congress 2010 in association with AAPS Annual Meeting & Exposition, New Orleans, 14-18 November.
The Translational Pharmaceutics platform has redefined early development processes by integrating the development and provision of drug products (formulation development, pharmaceutical analysis and GMP manufacturing) with clinical testing.
The Translational Pharmaceutics platform has redefined early development processes by integrating the development and provision of drug products (formulation development, pharmaceutical analysis and GMP manufacturing) with clinical testing.
Labels: laboratory, drug discovery
Quotient Bioresearch
Distribution agreement for GEM and cell culture reagents
Global Cell Solutions (GCS) and VWR International, LLC, a global laboratory supply and distribution company, announced they have entered into a non-exclusive North American distribution agreement. Under the terms, VWR will distribute GCS's portfolio of GEM magnetic microcarrier products offered with a wide variety of cell adhesion coatings.
Labels: laboratory, drug discovery
Global Cell Solutions
Pre-emptive pathogen reduction and pathogen inactivation
Although remarkable advances have been made in the prevention of the major transfusion-transmitted diseases, long intervals have transpired between the first recognition of transfusion risk and the implementation of a preventive strategy.
For hepatitis B virus, that interval was 30 years; for non-A non-B/hepatitis C virus, 15 years; and for human immunodeficiency virus, West Nile virus, Trypanosoma cruzi and bacteria, 3, 4, 5 and 18 years, respectively. In the existing reactive approach, there is a fundamental and inevitable delay before the government healthcare authorities can react; thus, infections are destined to occur.
For hepatitis B virus, that interval was 30 years; for non-A non-B/hepatitis C virus, 15 years; and for human immunodeficiency virus, West Nile virus, Trypanosoma cruzi and bacteria, 3, 4, 5 and 18 years, respectively. In the existing reactive approach, there is a fundamental and inevitable delay before the government healthcare authorities can react; thus, infections are destined to occur.
Labels: laboratory, drug discovery
Frost and Sullivan
Positive results in patients with chronic idiopathic constipation from a Phase IIb trial of A3309
Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial.
Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients. A3309 is a first-in-class IBAT inhibitor with minimal systemic exposure which is developed for the treatment of CIC and constipation-predominant irritable bowel syndrome (IBS-C).
Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients. A3309 is a first-in-class IBAT inhibitor with minimal systemic exposure which is developed for the treatment of CIC and constipation-predominant irritable bowel syndrome (IBS-C).
Labels: laboratory, drug discovery
Albireo
Analysis of antibody-antigen-complex structures to allow more efficient engineering of therapeutic antibodies
MorphoSys AG and Proteros Biostructures announced today that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural characterization of antibody-antigen-complexes.
MorphoSys will provide relevant antigen and antibody molecules, Proteros will provide advanced x-ray technology and computational chemistry know-how. The high resolution access to antibody-antigen-complex structures is expected to allow a faster and more efficient engineering of therapeutic antibodies.
MorphoSys will provide relevant antigen and antibody molecules, Proteros will provide advanced x-ray technology and computational chemistry know-how. The high resolution access to antibody-antigen-complex structures is expected to allow a faster and more efficient engineering of therapeutic antibodies.
Labels: laboratory, drug discovery
MorphoSys AG,
Proteros Biostructure
Combining CGH and SNP assays on same microarray, creates a unique cytogenetics tool
Agilent Technologies Inc today introduced the SurePrint G3 Human CGH+SNP microarray platform, an innovative system for simultaneous analysis of chromosomal copy number changes and copy-neutral aberrations. The system allows researchers to study the genetic basis of developmental disorders as well as many cancers.
This is the only two-colour CGH platform that can detect loss of heterozygosity/uniparental disomy (LOH/UPD) with 5- to 10-megabase resolution.
This is the only two-colour CGH platform that can detect loss of heterozygosity/uniparental disomy (LOH/UPD) with 5- to 10-megabase resolution.
Labels: laboratory, drug discovery
Agilent Technologies,
SurePrint G3
Monday, 11 October 2010
Drug improved survival for advanced prostate cancer patients
Phase III trial results presented today show a drug developed by British scientists can significantly extend overall survival for men with advanced prostate cancer.
Abiraterone acetate is a pill discovered at The Institute of Cancer Research (ICR) that treats aggressive prostate cancer, which each year kills 10,000 men in the UK.
Abiraterone acetate is a pill discovered at The Institute of Cancer Research (ICR) that treats aggressive prostate cancer, which each year kills 10,000 men in the UK.
Labels: laboratory, drug discovery
Institute of Cancer Research
Drug fingerprinting via HPLC/MS salt forms method
Thermo Fisher Scientific has developed a method for the identification, confirmation and quantitation of illicit drugs and their salt forms. This unique method combines high-performance liquid chromatography with mass spectrometry (HPLC/MS) to provide accurate simultaneous separation and detection of cations and anions in illicit drug salt forms.
The technique enables drug salt forms to be precisely identified and confirmed by two independent parameters - retention time and mass spectral signature, allowing forensic drug chemists to reliably analyze seized materials.
The technique enables drug salt forms to be precisely identified and confirmed by two independent parameters - retention time and mass spectral signature, allowing forensic drug chemists to reliably analyze seized materials.
Labels: laboratory, drug discovery
Thermo Fisher Scientific
Inkjet microarrayer platform
Arrayjet today announced that the KTH Royal Institute of Technology in Stockholm, has chosen its Marathon Inkjet Microarrayer for its Protein Array Technologies Group.
Headed by Dr Peter Nilsson, the group, which will also serve as an Arrayjet reference site, is based in the Department of Proteomics and forms part of the Human Protein Atlas project led by Professor Mathias Uhlén. The Marathon Inkjet Microarrayer was chosen as it will provide Dr Nilsson and colleagues with the flexibility to print their own arrays, at the exceptionally high quality and throughput levels they require.
Headed by Dr Peter Nilsson, the group, which will also serve as an Arrayjet reference site, is based in the Department of Proteomics and forms part of the Human Protein Atlas project led by Professor Mathias Uhlén. The Marathon Inkjet Microarrayer was chosen as it will provide Dr Nilsson and colleagues with the flexibility to print their own arrays, at the exceptionally high quality and throughput levels they require.
Labels: laboratory, drug discovery
Arrayjet,
Marathon Inkjet Microarrayer
Unconventional strategies to sustain pipelines and address global healthcare needs
To open 18th Annual BioPartnering Europe conference, Dr Anders Ekblom, Executive Vice President, Global Medicines Development at AstraZeneca, spoke about a commitment to innovation and AstraZeneca's approach to collaborations.
Michael S Johnson, Practice leader at Deloitte Recap LLC, gave his insights and a forecast on the changing landscape of deal structures and business models within the biotech industry. To conclude the morning keynote sessions, Dr David Nicholson, Senior Vice President for Worldwide Licensing and Knowledge Management at Merck & Co Inc, provided an update on today’s Merck and shared his perspectives on the current state of the pharmaceutical industry and the ongoing search for innovative compounds and technologies.
Michael S Johnson, Practice leader at Deloitte Recap LLC, gave his insights and a forecast on the changing landscape of deal structures and business models within the biotech industry. To conclude the morning keynote sessions, Dr David Nicholson, Senior Vice President for Worldwide Licensing and Knowledge Management at Merck & Co Inc, provided an update on today’s Merck and shared his perspectives on the current state of the pharmaceutical industry and the ongoing search for innovative compounds and technologies.
Labels: laboratory, drug discovery
BioPartnering Europe
KINAXO enters agreement with Bristol-Myers Squibb Company
KINAXO Biotechnologies GmbH announced today that Bristol-Myers Squibb Company has chosen KINAXO to support several of its drug discovery programs.
Under the terms of the agreement, KINAXO will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing discovery research at Bristol-Myers Squibb to enable more informed decisions at various stages of the drug discovery process, such as selecting the right compound for clinical development.
Dr Jutta Fritz, Head of Business Development at KINAXO commented: “We are very pleased to collaborate with Bristol-Myers Squibb, one of the most prestigious pharmaceutical companies in the world. We are looking forward to building a productive partnership with Bristol-Myers Squibb, and consider this move to be a major milestone in expanding our business in the United States.”
KINAXO Biotechnologies
Under the terms of the agreement, KINAXO will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing discovery research at Bristol-Myers Squibb to enable more informed decisions at various stages of the drug discovery process, such as selecting the right compound for clinical development.
Dr Jutta Fritz, Head of Business Development at KINAXO commented: “We are very pleased to collaborate with Bristol-Myers Squibb, one of the most prestigious pharmaceutical companies in the world. We are looking forward to building a productive partnership with Bristol-Myers Squibb, and consider this move to be a major milestone in expanding our business in the United States.”
KINAXO Biotechnologies
Labels: laboratory, drug discovery
Bristol-Myers Squibb Company,
KINAXO Biotechnologies GmbH
Subscribe to:
Posts (Atom)